 |
|
Liability for Adverse Events in Direct-to-Consumer Advertising
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In their article about direct-to-consumer advertising (DTCA), Dr Mello and colleagues1 discussed whether drug companies should share product liability relating to advertising claims. They concluded that learned intermediaries (ie, physicians) will probably need to continue to assume some of these risks. However, DTCA has the power to change patients' perspectives and personal risk-benefit analyses, leading them to want therapies or take risks they might not otherwise accept. Even learned intermediaries can fail in the face of overwhelming advertising pressures. Exaggerations or misleading representations present a danger for patients2 and I believe that they should lead to greater liability for the advertisers.
Contrast a physician describing a drug's ability to decrease the risk of cardiac events to a television advertisement for that same drug, which depicts a fit middle-aged man with young women following his every move. Although a physician would be likely to discuss the drug's risks . . . [Full Text of this Article]
RELATED ARTICLES
Liability for Adverse Events in Direct-to-Consumer Advertising
George W. Evans and Arnold I. Friede
JAMA. 2003;289(20):2646-2647.
EXTRACT
| FULL TEXT
Liability for Adverse Events in Direct-to-Consumer Advertising—Reply
Michelle M. Mello, Meredith B. Rosenthal, and Peter J. Neumann
JAMA. 2003;289(20):2647.
EXTRACT
| FULL TEXT
Direct-to-Consumer Advertising and Shared Liability for Pharmaceutical Manufacturers
Michelle M. Mello, Meredith Rosenthal, and Peter J. Neumann
JAMA. 2003;289(4):477-481.
EXTRACT
| FULL TEXT
Misleading Advertisements
Brian Vastag
JAMA. 2003;289(1):35.
EXTRACT
| FULL TEXT
|
